Show simple item record

dc.contributor.authorFogarty, H
dc.contributor.authorByrne, M
dc.contributor.authorO’Connell, NM
dc.contributor.authorRyan, K
dc.contributor.authorWhite, B
dc.contributor.authorO’Donnell, JS
dc.contributor.authorLavin, M
dc.date.accessioned2018-06-12T10:56:40Z
dc.date.available2018-06-12T10:56:40Z
dc.date.issued2018-05
dc.identifier.urihttp://hdl.handle.net/10147/623062
dc.description.abstractFactor XIII (FXIII) is a plasma clotting protein involved in clot stabilization. Severe FXIII deficiency may present with severe, even fatal bleeding. Critically however, routine coagulation assays may be normal and only specific FXIII assays will detect the abnormality. Herein we discuss a case report of a patient with acquired FXIII deficiency in order to highlight the clinical challenges associated with establishing the diagnosis and discuss the treatment approach. A 70-year-old man presented with a gluteal haematoma despite no preceding personal history of bleeding. Extensive initial haemostatic investigations were normal until a specific FXIII assay showed a marked reduction in FXIII levels. With directed treatment, bleeding episodes ceased and remission was achieved. Clinical awareness of FXIII deficiency is important, so appropriate testing can be implemented in patients with unexplained bleeding diatheses, particularly those in whom bleeding responds poorly to standard replacement therapy.
dc.language.isoenen
dc.publisherIrish Medical Journalen
dc.subjectDEFICIENCYen
dc.subjectBLOODen
dc.subject.otherPLASMAen
dc.titleAcquired Factor Xiii Deficiency: An Uncommon But Easily Missed Cause Of Severe Bleedingen
dc.typeArticleen
dc.identifier.journalIrish Medical Journalen
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
html.description.abstractFactor XIII (FXIII) is a plasma clotting protein involved in clot stabilization. Severe FXIII deficiency may present with severe, even fatal bleeding. Critically however, routine coagulation assays may be normal and only specific FXIII assays will detect the abnormality. Herein we discuss a case report of a patient with acquired FXIII deficiency in order to highlight the clinical challenges associated with establishing the diagnosis and discuss the treatment approach. A 70-year-old man presented with a gluteal haematoma despite no preceding personal history of bleeding. Extensive initial haemostatic investigations were normal until a specific FXIII assay showed a marked reduction in FXIII levels. With directed treatment, bleeding episodes ceased and remission was achieved. Clinical awareness of FXIII deficiency is important, so appropriate testing can be implemented in patients with unexplained bleeding diatheses, particularly those in whom bleeding responds poorly to standard replacement therapy.


Files in this item

Thumbnail
Name:
art9.html
Size:
29.62Kb
Format:
HTML
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record